PROTAC RIPK degrader-2

Cat. No.: HY-111866

CAS No.: 1801547-16-9

Molecular Formula: $C_{52}H_{65}N_7O_{11}S_3$

Molecular Weight: 1060.31

Target: RIP kinase; PROTACs

Pathway: Apoptosis; PROTAC

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 150 mg/mL (141.47 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9431 mL	4.7156 mL	9.4312 mL
	5 mM	0.1886 mL	0.9431 mL	1.8862 mL
	10 mM	0.0943 mL	0.4716 mL	0.9431 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 7.5 mg/mL (7.07 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 7.5 mg/mL (7.07 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes[1][2].

IC_{50} & Target		
	RIPK2	VHL

REFERENCES

[1]. Wang C, et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906.

[2]. Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA